Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jaguar Animal Health ( (JAGX) ) has shared an update.
On June 27, 2025, Jaguar Health, Inc. engaged in a transaction with Iliad Research and Trading, L.P., issuing 170 shares of Series M Perpetual Preferred Stock. Later, on December 9 and December 11, 2025, Jaguar Health entered into two separate exchange agreements with Iliad, resulting in the issuance of a total of 440,000 shares of common stock and pre-funded warrants to purchase 1,609,372 shares in exchange for 91 shares of Series M Preferred Stock, which were subsequently cancelled. These transactions reflect strategic financial maneuvers by Jaguar Health to manage its stock and capital structure, potentially impacting its market positioning and shareholder dynamics.
The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
Jaguar Animal Health’s overall stock score is primarily impacted by its poor financial performance, characterized by high leverage and consistent losses. While there is some positive sentiment from recent earnings and clinical advancements, the technical indicators and valuation metrics remain weak, contributing to a low overall score.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Average Trading Volume: 218,299
Technical Sentiment Signal: Sell
Current Market Cap: $4.97M
For an in-depth examination of JAGX stock, go to TipRanks’ Overview page.